Article

A high physical symptom count reduces the effectiveness of treatment for depression, independently of chronic medical conditions

Department of General Practice and the EMGO(+) Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands. Electronic address: .
Journal of psychosomatic research (Impact Factor: 2.84). 03/2013; 74(3):179-85. DOI: 10.1016/j.jpsychores.2013.01.004
Source: PubMed

ABSTRACT To assess to what extent a high physical symptom count influences the effect of treatment for major depressive disorder (MDD), and whether or not actual comorbid medical conditions explain this relationship.
Secondary data-analysis on a cluster-randomized trial in primary care, comparing the effectiveness of collaborative care with care as usual (CAU). MDD was measured using the PHQ-9. The Physical Symptoms Questionnaire (PSQ) was filled out at baseline by 115 patients (77.2% of those who entered the trial). Multilevel logistic regression models were used to test whether a high physical symptom count predicted lack of response to treatment, adding interaction terms to test differential effects on collaborative care versus CAU.
A high physical symptom count negatively influenced the effect of both collaborative care and care as usual (no interaction). Specifically, a high physical symptom count predicted lack of response in both conditions at 3 (odds ratio=6.8), 6 (OR=4.1), and 9months follow-up (OR=6.4). This was not explained by chronic physical illness.
In this RCT, patients with MDD accompanied by a high physical symptom count benefited less from treatment for MDD in primary care, regardless of the type of treatment (either collaborative care or CAU). This was not explained by the presence of comorbid medical conditions. Further research is needed to improve treatment for MDD accompanied by a high physical symptom count, although collaborative care for depression is still more effective than CAU for this group of patients. Trial registration: Dutch trial register ISRCTN15266438.

Download full-text

Full-text

Available from: Harm Van Marwijk, Dec 08, 2014
0 Followers
 · 
90 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Samenvatting Huijbregts KM, de Jong FJ, Van Marwijk HWJ, Beekman ATF, Hakkaart-Roijen L, Van der Feltz-Cornelis CM. Collaborative care voor depressieve patiënten. Huisarts Wet 2013;56(5):210-3. Achtergrond Van alle patiënten bij wie een depressie wordt vaststeld, krijgt de meerderheid een behandeling in de eerste lijn. Lang niet al deze patiënten krijgen zorg conform de NHG-Standaard. Mogelijk speelt hierbij mee dat huisartsen te weinig tijd beschikbaar hebben om regie te voeren bij deze patiënten, die met complexe psychosociale problemen te kampen hebben. Zogeheten competing demands (deze patiënten komen zelden alleen met een depressie) kunnen hierbij ook een rol spelen. Het collaborative care-model kan een oplossing bieden, aangezien de huisarts hierbij ondersteuning krijgt van een caremanager in de eerste lijn, die bepaalde aspecten van de zorg overneemt, zoals monitoring en kortdurende gespreksbehandeling, Problem Solving Treatment (PST). Ook is een consulent psychiater gemakkelijk beschikbaar voor overleg en kunnen de caremanager en de huisarts gebruikmaken van een web-based patiëntvolgsysteem, dat advies geeft over de te volgen stappen. Methode In een clustergerandomiseerde trial vergeleken we collaborative care met de gebruikelijke Nederlandse huisartsenzorg. We randomiseerden 18 gezondheidscentra. Honderdvijftig patiënten kwamen in aanmerking voor deelname na screening met de PHQ-9 (een vragenlijst die op basis van de 9 DSM-IV-criteria voor depressie een ernstscore tussen de 0 en 27 genereert), dan wel na aanmelding door de deelnemende huisartsen. De huisartsen meldden 56 patiënten aan, allen op een na in de collaborative care-groep. Vijfenveertig patiënten kregen collaborative care na identificatie door screening en 49 patiënten kregen gebruikelijke zorg (allen behalve één na screening). De primaire uitkomstmaat was behandelrespons (een afname van 50% op de PHQ-9-score tussen baseline en een vervolgmeting). Resultaten Collaborative care bleek effectiever dan de gebruikelijke zorg na 3 (oddsratio 5,2 (95%-BI 1,41-16,09), number needed to treat 2) en 9 maanden (oddsratio 5,6 (95%-BI 1,40-22,58), number needed to treat 3). Conclusie Collaborative care bleek zowel in de aangemelde als in de gescreende groep effectiever dan de gebruikelijke zorg. De lage numbers needed to treat getuigen hiervan. Een beperking van het onderzoek was wel het relatief hoge percentage patiënten (36,5%) dat een of meer van de vragenlijsten niet terugstuurde. Ook screening voor depressie per post bleek lastig, waardoor de inclusie aanvankelijk traag verliep. Aanmelding via de huisarts bleek aanmerkelijk succesvoller. De huisartsen bleken in staat om een groep patiënten te identificeren die veel baat had bij de interventie. Implementatie van collaborative care in de Nederlandse eerste lijn lijkt al met al zeker de moeite waard.
    Huisarts en wetenschap 05/2013; 56(5). DOI:10.1007/s12445-013-0124-0
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) changed the term "somatoform disorders" to "somatic symptom and related disorders" and further modified diagnostic labels and criteria. We review evidence for the validity of the new criteria, specifically of somatic symptom disorder (SSD), and present a critical discussion of unsolved and new problems. We also provide an update of mechanisms and interventions that have been empirically evaluated in somatoform disorders. For many mechanisms, it is unclear whether their role can be easily transposed to SSD. Therefore more research is needed on the similarities and differences between medically unexplained and medically explained conditions. To overcome the obvious shortcomings of the current classification, we offer a modification of this DSM-5 section as well as a crossover system to apply these criteria for somatic symptom and related disorders. This proposal allows working with DSM-5 but also continuing successful lines of research with concepts such as hypochondriasis/illness anxiety, chronic pain, and medically unexplained versus medically explained syndromes. Expected final online publication date for the Annual Review of Clinical Psychology Volume 10 is March 20, 2014. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates.
    Annual Review of Clinical Psychology 01/2014; 10. DOI:10.1146/annurev-clinpsy-032813-153745 · 12.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Using data from the GenPod trial this study investigates: (i) if depressed individuals with multiple physical symptoms have a poorer response to antidepressants before and after adjustment for baseline Beck Depression Inventory II (BDI-II); and (ii) if reboxetine is more effective than citalopram in depression with multiple physical symptoms. Methods Linear regression models were used to estimate differences in mean BDI-II score at 6 and 12 weeks. Results Before adjusting for baseline BDI-II, the difference in mean BDI-II score between no and multiple physical symptoms was 4.5 (95% CI 1.87, 7.14) at 6 weeks, 4.51 (95% CI 1.60, 7.42) at 12 weeks. After adjustment for baseline BDI-II, there was no evidence of a difference in outcome according to physical symptoms with a difference in mean BDI-II of 2.17 (95% CI −0.39, 4.73) at 6 weeks and 2.43 (95% CI −0.46, 5.32) at 12 weeks. There was no evidence that reboxetine was more effective than citalopram in those with multiple physical symptoms at 6 (P=0.18) or 12 weeks (P=0.24). Limitations Differential non-adherence between treatment arms has the potential to bias estimates of treatment efficacy. Conclusion Multiple physical symptoms predict response to antidepressants, but not after adjustment for baseline depression severity. Physical symptoms could be a marker of severe depression rather than an independent prognostic factor and depression should be considered in patients with multiple physical symptoms. Treatment with reboxetine conferred no advantage over citalopram in those with physical symptoms, and it is less well tolerated.
    Journal of Affective Disorders 07/2014; 163:40–46. DOI:10.1016/j.jad.2014.03.051 · 3.71 Impact Factor